-
Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone)
-
Mitsubishi Tanabe Pharma America Announces Presentations at Virtual 33rd International Symposium on ALS/MND
-
Mitsubishi Tanabe Pharma America Presents Interim Data from REFINE-ALS Biomarker Study at 21st Annual NEALS Meeting
-
Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting
-
Mitsubishi Tanabe Pharma America Celebrates Nearly 2,000 ALS Patients treated with RADICAVA ORS® (edaravone)
-
Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS® (edaravone) at 2022 AANEM Annual Meeting
-
Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA® (edaravone)
-
Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone)
-
RADICAVA ORS® (edaravone) Now Available in the U.S. for the Treatment of ALS
-
Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS